Pfizer Inc. (PFE)
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.
Pfizer: It Could Be A Bargain
When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Monday, underscoring the safety of vaccination during pregnancy amid mounting evidence of the severe health risks infections can cause for mothers and babies.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with the concerns and fears of its workers.
Is Pfizer Stock a Buy?
Pfizer shares have suffered a painful slide as pandemic revenue dried up. But management is committed to maintaining and growing the dividend.
2 Healthcare Stocks That Are Screaming Buys in June
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.
This Recent FDA Approval Is Bad News for Pfizer
Pfizer dominates the pneumococcal vaccine market. However, Merck has obtained approval for a pneumococcal vaccine Merck's new medication could become the new top seller for this indication.
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.
